Tyme Technologies Inc (TYME):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Tyme Technologies Inc (TYME) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9370
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tyme Technologies Inc (Tyme) is a clinical-stage pharmaceutical company. The company focused on discovering and developing targeted cancer therapeutics for oncology indications. It develops clinical program SM-88, an oral tyrosine-based therapy that is currently in Phase II development for prostate cancer. Tyme develops SM-88, a combination therapy utilizing proprietary dysfunctional tyrosine derivative as the backbone. The company offers SM-88 tyrosine derivative, which is designed to be absorbed by cancer cell as if it were a functional tyrosine, but after uptake, interrupt metabolic processes like protein synthesis. The company’s therapeutic intervention is designed to compromise cancer’s cellular defences and exploits its innate metabolic weaknesses, which leads to cell death through oxidative stress and exposing cancer to the body’s natural immune system. Tyme is headquartered in New York, the US.

Tyme Technologies Inc (TYME) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tyme Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Tyme Technologies Enters into Collaboration Agreement with Joseph Ahmed 11
Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 12
Merger 13
Tyme Technologies Merges with Tyme in Reverse Merger Transaction 13
Equity Offering 14
Tyme Technologies Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD23.3 Million 14
Tyme Technologies Raises USD8.2 Million in Private Placement of Shares and Warrants 16
Tyme Technologies Files Shelf Registration with SEC To Raise USD250 Million 17
Tyme Technologies Raises USD3.1 Million in Private Placement of Shares 18
Tyme Technologies Raises USD7 Million in Private Placement of Common Stock 19
Tyme Technologies Inc – Key Competitors 20
Tyme Technologies Inc – Key Employees 21
Tyme Technologies Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Jul 30, 2018: Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019 23
Corporate Communications 25
Oct 15, 2018: Tyme Technologies names Michele Korfin as Chief Commercial Officer 25
Sep 18, 2018: Tyme Technologies names Douglas A. Michels as Board Director 26
Feb 21, 2018: Tyme Technologies Appoints Tommy G. Thompson to Board of Directors 27
Sep 14, 2017: Tyme Adds Distinguished Drug Developer, Briggs W. Morrison, M.D. to Advisory Board 28
Aug 09, 2017: Tyme Appoints Dr. Jonathan Eckard as Chief Scientific Affairs Officer 29
Mar 29, 2017: Tyme Technologies Announces Two New Board of Director Appointments — David Carberry and James Biehl 30
Mar 23, 2017: Tyme Appoints Ben Taylor as President and Chief Financial Officer 31
Mar 02, 2017: Tyme Technologies Appoints Healthcare Veteran Paul L. Sturman as Independent Director 32
Product News 33
06/05/2017: Tyme Technologies Presents Positive Interim Clinical Data in Recurrent, Non-Metastatic Prostate Cancer at ASCO 2017 33
05/22/2017: Tyme Technologies to Present New Clinical Data for Investigational Drug Candidate SM-88 at 2017 ASCO Annual Meeting 34
01/06/2017: Tyme Technologies Announces Hiring of Shabnam Stanicky as Clinical Operations Officer 35
01/05/2017: Tyme Technologies Advances SM-88 into the Second Stage of its Phase Ib/II Prostate Cancer Trial 36
Other Significant Developments 37
Nov 05, 2018: Tyme provides clinical and corporate update for fiscal 2Q 2019 37
Apr 09, 2018: Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018 38
Feb 07, 2018: Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017 39
Nov 08, 2017: Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017 40
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tyme Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tyme Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tyme Technologies Enters into Collaboration Agreement with Joseph Ahmed 11
Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 12
Tyme Technologies Merges with Tyme in Reverse Merger Transaction 13
Tyme Technologies Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD23.3 Million 14
Tyme Technologies Raises USD8.2 Million in Private Placement of Shares and Warrants 16
Tyme Technologies Files Shelf Registration with SEC To Raise USD250 Million 17
Tyme Technologies Raises USD3.1 Million in Private Placement of Shares 18
Tyme Technologies Raises USD7 Million in Private Placement of Common Stock 19
Tyme Technologies Inc, Key Competitors 20
Tyme Technologies Inc, Key Employees 21

List of Figures
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Tyme Technologies Inc (TYME):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • REV Group Inc (REVG):企業の財務・戦略的SWOT分析
    REV Group Inc (REVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Institut Pasteur-製薬・医療分野:企業M&A・提携分析
    Summary Institut Pasteur is a non-profit foundation that provides research, health services and education. The institute offers research in the areas of biology, genomes and genetics, immunology, infection and epidemiology, microbiology, neuroscience, parasitology and mycology, structural biology an …
  • KPMG International Coop:企業の戦略的SWOT分析
    KPMG International Coop - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • New York Power Authority:企業の戦略・SWOT・財務分析
    New York Power Authority - Strategy, SWOT and Corporate Finance Report Summary New York Power Authority - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Advanced BioScience Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Advanced BioScience Laboratories Inc (ABL), a subsidiary of Institut Merieux SA is a contract research and manufacturing company that provides services to life sciences industry. The company develops vaccines, therapeutics and other biologic products. It provides proof-of-concept in vivo stu …
  • CSS Industries, Inc. (CSS):企業の財務・戦略的SWOT分析
    CSS Industries, Inc. (CSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Freshfields Bruckhaus Deringer LLP:企業の戦略・SWOT・財務情報
    Freshfields Bruckhaus Deringer LLP - Strategy, SWOT and Corporate Finance Report Summary Freshfields Bruckhaus Deringer LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • The Co-operative Bank Plc:企業の戦略・SWOT・財務情報
    The Co-operative Bank Plc - Strategy, SWOT and Corporate Finance Report Summary The Co-operative Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Solon Eiendom ASA (SOLON):企業の財務・戦略的SWOT分析
    Solon Eiendom ASA (SOLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SuppreMol GmbH-製薬・医療分野:企業M&A・提携分析
    Summary SuppreMol GmbH (SuppreMol), a subsidiary of Baxalta Inc, is a biopharmaceutical company that develops therapeutics in the areas of autoimmune, chronic inflammatory diseases, and allergies. The company’s lead drug candidate is extensively profiled in in-vitro, ex-vivo and in-vivo experiments. …
  • Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Unum Therapeutics Inc (Unum Therapeutics) is a clinical-stage bio-pharmaceutical company focused on the development and commercialization of novel antibody-coupled cellular immunotherapies to fight cancers. Its pipeline product portfolio include ACTR087 + rituximab, a CD20 targeting chimeric …
  • Translate Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Translate Bio Inc (Translate Bio), formerly RaNA Therapeutics Inc is a healthcare service provider that develops therapies which targets RNA within cells in the body to selectively activate protein expression. The company provides platform oligonucleotides (oligos) are molecules designed to …
  • Marathon Oil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Marathon Oil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Marathon Oil Corp (MRO) is independent energy company, which explores, produces and markets liquid hydrocarbons and natural gas. It focuses mainly on unconventional resource plays in the US with op …
  • TWi Pharmaceuticals Inc (4180)-製薬・医療分野:企業M&A・提携分析
    Summary TWi Pharmaceuticals Inc (TWi), formerly Anchen Pharmaceuticals (Taiwan) Inc is a manufacturer of high barrier generics drugs. The company’s products include donepezil hydrochloride tablets, hydroquinone cream, hydroquinone time release cream, megestrol acetate oral suspension and nifedipine …
  • Dufry AG (DUFN):企業の財務・戦略的SWOT分析
    Dufry AG (DUFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Asseco Business Solutions SA (ABS):企業の財務・戦略的SWOT分析
    Asseco Business Solutions SA (ABS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • TransMontaigne Product Services LLC:企業の戦略・SWOT・財務情報
    TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report Summary TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • International Finance Corporation:企業の戦略的SWOT分析
    International Finance Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Covance Inc:企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Enable Midstream Partners LP (ENBL):石油・ガス:M&Aディール及び事業提携情報
    Summary Enable Midstream Partners, LP (Enable), a subsidiary of CenterPoint Energy Inc, owns, operates, and develops natural gas and crude oil infrastructure assets. It is a limited partnership among CenterPoint Energy, OGE Energy and ArcLight Capital Partners, LLC. The company offers crude oil and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆